Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Prescribed Painkiller Not Effective in Controlling Back Pain

December 10, 2014 4:35 pm | by University of Rochester | News | Comments

A new study out in the journal Neurology shows that pregabalin is not effective in controlling the pain associated with lumbar spinal stenosis, the most common type of chronic lower back pain in older adults. Read more...

TOPICS:

Ebola Fighters Named Time Person of The Year

December 10, 2014 2:34 pm | by Kiley Armstrong - Associated Press | News | Comments

Time Magazine named doctors, nurses, and others fighting Ebola as 2014's Person of the Year. Read more...                          

TOPICS:

Pinpointing Part of Brain That Triggers Addiction

December 10, 2014 1:14 pm | by University of Michigan | News | Comments

Activating the brain's amygdala, an almond-shaped mass that processes emotions, can create an addictive, intense desire for sugary foods, a new University of Michigan study found. Rewards such as sweet tasty food or even addictive drugs like alcohol or cocaine can be extremely attractive when this brain structure is triggered. Read more...

TOPICS:
Advertisement

Metal Test Could Help Diagnose Breast Cancer Early

December 10, 2014 1:06 pm | by University of Oxford | News | Comments

A team, led by Oxford University scientists, took techniques normally used to analyse trace metal isotopes for studying climate change and planetary formation and applied them to how the human body processes metals. Read more...                                    

TOPICS:

Ohio Lawmakers Debate Execution Drugmaker Bill

December 10, 2014 1:01 pm | by Andrew Welsch-Huggins, AP Legal Affairs Writer - Associated Press | News | Comments

Companies providing Ohio with lethal injection drugs would have their names shielded for at least 20 years, under a bill scheduled for a possible vote that lawmakers say is needed to restart executions in the state. Read more...                                  

TOPICS:

Mylan Launches Generic Versions of Celebrex Capsules

December 10, 2014 12:51 pm | News | Comments

Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Read more...

TOPICS:

Developed Drug Effective Against Antibiotic-Resistant 'Superbugs'

December 10, 2014 12:45 pm | by University of Pittsburgh | News | Comments

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research (CVR) is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called “superbugs” resistant to almost all existing antibiotics, which plague hospitals and nursing homes. Read more...

TOPICS:

Generic Antiepilepsy Drugs Have Minimal Differences: Study

December 10, 2014 12:32 pm | by University of Cincinnati | News | Comments

A comparison of two of the most disparate approved generic antiepileptic drugs found minimal differences when compared under rigorous testing procedures in people with epilepsy, according to research presented by a University of Cincinnati (UC) clinician-researcher. Read more...

TOPICS:
Advertisement

Combo Treatment Benefits Women with Metastatic Breast Cancer

December 10, 2014 10:07 am | News | Comments

Results of a Phase 2, open-label, dose-confirmation study of eribulin in combination with capecitabine, suggests that this therapy is efficacious in women with metastatic breast cancer (overall response rate 42.9% and clinical benefit rate 57.1%), with a safety and tolerability profile consistent with previous data. Read more...

TOPICS:

Simeprevir-Based Therapy: Cost-Effective HCV Treatment

December 10, 2014 9:44 am | by UPenn | News | Comments

Researchers at Penn Medicine have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic HCV as telaprevir with interferon and ribavirin, the standard of care in developing countries. Read more...

TOPICS:

Roche's Preeclampsia Test Could Predict At-Risk Pregnant Women

December 10, 2014 9:26 am | News | Comments

Results of the PROGNOSIS study presented at the 20th World Congress on Controversies in Obstetrics, Gynecology & Infertility in Paris, demonstrate the prognostic value of the Elecsys preeclampsia test from Roche to predict the absence of preeclampsia for one week and the development of preeclampsia within the subsequent four weeks. Read more...

TOPICS:

Drug Target Discovery May Improve Schizophrenia Treatment

December 10, 2014 9:18 am | News | Comments

Scientists have identified a novel drug target that could lead to the development of better antipsychotic medications. Read more...                      

TOPICS:

Supplement May Lower CVD Risk in People of Low Birth Weight

December 10, 2014 9:07 am | by University of Cambridge | News | Comments

A simple supplement could be a safe and cost-effective way of reducing heart disease in individuals born with a low birth weight. Read more...                    

TOPICS:

Debt and Hunger at Birthplace of Ebola

December 10, 2014 8:48 am | by Michelle Faul - Associated Press | News | Comments

Life is unforgiving in this part of the world, and people often lose their children to cholera, malaria, measles, typhoid, Lassa fever and a host of other illnesses that have no name. Read more...           

TOPICS:

Laughing Gas Studied as Depression Treatment

December 9, 2014 3:22 pm | by Jim Dryden, Washington University in St. Louis | News | Comments

Nitrous Oxide has shown early promise as a potential treatment for severe depression in patients whose symptoms don’t respond to standard therapies. Read more...                 

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading